LCTX Lineage Cell Therapeutics Inc

$LCTX Based on the totality of information I believe there is a 90-95% probability of Roche moving Opregen forward which should result in a multiple increase in the share price. I have sized appropriately. Good luck to all.

$LCTX $NWBO Clarifying my previous comment: Aging populations don’t need more symptom‑management drugs — they need therapies that restore biological function. That’s upstream medicine. LCTX is building cell‑replacement platforms. NWBO is building immune‑retraining platforms. Both are early, but both align with where medicine has to go. Upstream isn’t hype — it’s necessity.

$LCTX Also in its Thursday presentation, Roche announced the discontinuation several early-stage trials. These included Phase 1 studies of the small-molecule RG6327 for geographic atrophy, the antibody enzelkitug for solid tumors, the TMEM16A potentiator RG6421 for muco-obstructive respiratory disease, RG6622 for coronary artery disease, the antisense oligonucleotide RG6627 for Alzheimer’s disease and the CDK blocker RG6795 for breast cancer.

$LCTX $NWBO What does an Aging America and World ideally need from medicine in coming years? Not downstream medications with numerous side effects, but upstream solutions that work with your own body. LCTX has solutions to "Replace and Restore" malfunctioning body systems and manufacture cells for other Cell Therapeutics companies. NWBO has the ability to retrain one's own immune system to work like it should to attack solid tumors, and to retrain other systems to combat things like heart disease, diabetes and dementia. Upstream is the Future of Medicine. It's logical and obvious.

$LCTX Soon the work done by Culley and team will not seem impossible at all. Restoring eyesight, Curing Diabetes, renewed mobility!! Tall tasks to undertake by a small company with a Budget of 30 M per year... we have Lots to be thankful for. Every extraordinary achievement begins as something that seems out of reach. The difference between those who dream and those who accomplish extraordinary things is often the willingness to keep going when the outcome is uncertain, the obstacles are enormous, and nobody else believes it can be done. Don’t let the difficulty of the journey convince you that the destination is impossible.

$LCTX $NWBO The two most likely small biotech companies to have major impacts on medicine in the next two years. Each with ridiculously low M Caps below 300M. Neither company is a one trick pony. Each is truly a Platform company which the market totally misses right now. Big Pharma needs to partner with the Platform(s) rather than suppress the market caps.

$LCTX Some of Roche’s wins will have an element of luck, but its ruthlessness is also likely a factor. The company is known for cutting pipeline assets early at the first sign of underperformance or expectation of a tricky market entry. And the past quarter was no exception.

$LCTX billions of dollars thrown all over the world for anything related to technology. Well, a human body is the greatest piece of technology and nothing’s being given to biotech these days with over 200 million people subjected to some form of macular degeneration. The numbers here are outstanding if lineage is able to harness a little piece of this market through the math they’re thrown in stock away. It should be over five bucks in today’s world

$LCTX never sold one share of $LCTX , science , moral and ethical issue with dry AMD patients therapy is more important to me that money …. I live very comfortable, thank you

$LCTX FDA issued another accelerated approval for a DNA-bases immunotherapy. ION, their stock was up 240% after hours ....They continue to be pursuing faster approvals for the "new" direction in medicine. i.e.....DNA, Stem cells....This is good for us.

$LCTX AI review Islet cells. The potentially valuable achievement for LCTX is that it may be solving the upstream manufacturing bottleneck before trying to scale the finished islets. If it can demonstrate that the same process feeds islet differentiation reliably, that would be a meaningful competitive advantage. The next milestone I would watch most closely is successful differentiation of the expanded cells into islet precursors, followed by evidence that the process can deliver consistent yields at larger volumes. That would help establish whether Lineage's manufacturing lead is real and transferable to a future hypoimmune diabetes therapy.

$LCTX Roche could certainly show a bit more empathy toward the small, courageous Lineage (and its shareholders). In turn, Lineage should perhaps more actively seek out other partners for different projects.

$LCTX It should not be ignored that Roche Genentech is developing/strengthening its cell therapy capabilities. It also has ambitions regarding diabetes therapies. And, they have an existing partner that is emerging as a leader in this area. It’s just a waiting game for LCTX holders.

$LCTX 2M going into the last few minutes with 8% increase, would enjoy it staying above $1 going forward. Hopefully good thoughts going into the earnings report next month—or any special news coming soon.

$LCTX I will say it again. The most compelling near term catalyst is the mass production of islet cells. If LCTX can demonstrate the ability to use AlloScope to economically produce islet cells at scale, this becomes a 15+ billion dollar company.

$LCTX I'm glad for the uptick today, but nothing changed on the ride down or the way up. LCTX and Roche keep on doing the work, we will see it in the stock price eventually. We just do not know when, but it will happen.

$LCTX FOLKS! I don't have enough fingers/toes over the years to count my Takeouts/Mergers etc. I will get right to the point! $4.00-6.00 per share was my original price. $7.00-8.00 is more acceptable to myself and ARMY members who have held this for years! $9.00-11.00 is what it should be listed for with current assets/mfg capabilities. With all that being said, "I know how these deals end up" so I have warned my ARMY members we're looking @ $4.00-8.00 and I can't do anything about the future IP and billions of unlocked value. The guy with the checkbook and the very large checkbook will decide what the total value of Lineage is....................

$LCTX you know what they say, when Andy Blidy talks, people listen. Could have been E.F. Hutton though. I forget.

$LCTX Shorts will be working overtime in the next three weeks to keep price under $1.00 because of Russell Index reconstitution on October 30 ,trying to get shares to cover their short positions if LCTX gets removed from Russell.

$LCTX In the last few days,the spread between bid and ask has been much larger than normal.Looks like someone is trying to accumulate stock.